Related references
Note: Only part of the references are listed.High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
Mars B. van 't Veer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
Thomas M. Habermann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Annina Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Progress in Mantle-Cell Lymphoma
Peter Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Peter Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
P. Martin et al.
ANNALS OF ONCOLOGY (2008)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler et al.
BLOOD (2008)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma
Andrew M. Evens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Advances in the understanding of mantle cell lymphoma
Pedro Jares et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group
David J. Inwards et al.
CANCER (2008)
Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
Yuhong Zhou et al.
CANCER (2008)
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma - A phase 2 trial in the North Central Cancer Treatment Group
Stephen M. Ansell et al.
CANCER (2008)
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma
Amrita Krishnan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy
G. Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue
Elena Hartmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Peter H. Wiernik et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
K. Sue Robinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphoma
Daan Dierickx et al.
LEUKEMIA & LYMPHOMA (2008)
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma
Morton Coleman et al.
LEUKEMIA & LYMPHOMA (2008)
What is the real risk of central nervous system involvement in mantle cell lymphoma?
Saar Gill et al.
LEUKEMIA & LYMPHOMA (2008)
Positron emission tomography in mantle cell lymphoma
Lieselot Brepoels et al.
LEUKEMIA & LYMPHOMA (2008)
[18F] fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma
Saar Gill et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade lymphoma Study Group
Olaf Determann et al.
BLOOD (2008)
Central nervous system involvement in mantle cell lymphoma
A. Ferrer et al.
ANNALS OF ONCOLOGY (2008)
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome
P. Corradini et al.
LEUKEMIA (2007)
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics
Pedro Jares et al.
NATURE REVIEWS CANCER (2007)
The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67gallium scintigraphy in the evaluation of lymphoma -: Relation to histologic subtypes-based on the World Health Organization Classification
Norifumi Tsukamoto et al.
CANCER (2007)
Leukemic involvement is a common feature in mantle cell lymphoma
Ana Ferrer et al.
CANCER (2007)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
Holger Schulz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2007)
The cellular origin of mantle cell lymphoma
Francesco Bertoni et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
Peter Dreger et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner et al.
BLOOD (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gastrointestinal involvement in mantle cell lymphoma:: A prospective clinic, endoscopic, and pathologic study
Antonio Salar et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network
B. S. Kahl et al.
ANNALS OF ONCOLOGY (2006)
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas - Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group
Christina Nickenig et al.
CANCER (2006)
Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT)
Benjamin D. Rosenbluth et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Update on the molecular biology of mantle cell lymphoma
F Bertoni et al.
HEMATOLOGICAL ONCOLOGY (2006)
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma:: results of a randomised phase III trial (OSHO# 19)
M Herold et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2006)
Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma
D Bauwens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL):: a clinicopathological study from the European MCL Network
M Tiemann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Stem cell transplantation for mantle cell lymphoma: if, when and how?
TL Kiss et al.
BONE MARROW TRANSPLANTATION (2005)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
MJ Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP
DW Thomas et al.
LEUKEMIA & LYMPHOMA (2005)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK)
M Ghielmini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
J Mangel et al.
ANNALS OF ONCOLOGY (2004)
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma
MB Maris et al.
BLOOD (2004)
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
H Kaufmann et al.
BLOOD (2004)
Transplantation in patients with diffuse mantle cell lymphoma in first disease remission the prognostic value of β2-microglobulin and the tumor score
IF Khouri et al.
CANCER (2003)
Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes
L Nodit et al.
HUMAN PATHOLOGY (2003)
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
AM Gianni et al.
BLOOD (2003)
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease
J Orchard et al.
BLOOD (2003)
Outcome of autologous transplantation for mantle cell lymphoma:: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant registries
E Vandenberghe et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
JE Romaguera et al.
CANCER (2003)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
A Rosenwald et al.
CANCER CELL (2003)
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma
IF Khouri et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
AK Gopal et al.
BLOOD (2002)
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival
OM Howard et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Blastic variant of mantle cell lymphoma:: a rare but highly aggressive subtype
M Bernard et al.
LEUKEMIA (2001)
Phosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma
BJ Cohen et al.
LEUKEMIA & LYMPHOMA (2001)
Mantle cell lymphoma, in leukaemic phase with prominent splenomegaly. A report of eight cases with similar clinical presentation and aggressive outcome
TJ Molina et al.
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY (2000)
Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?
L Orlando et al.
ANNALS OF ONCOLOGY (2000)
Untreated aggressive mantle cell lymphoma: Results with intensive chemotherapy without stem cell transplant in elderly patients
JE Romaguera et al.
LEUKEMIA & LYMPHOMA (2000)
Share Paper
